FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots

By LAURAN NEERGAARD and MATTHEW PERRONE

WASHINGTON (AP) — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncertainty about updates to other vaccines, too.

Related Articles

• Emerging from a collective silence, U.S. universities organize to fight President Trump
• Rep. Gerry Connolly steps down...